

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

CHARO et al.

Appn. No.: 09/763,462

Filed: May 1, 2001

Title: METHOD OF DNA VACCINATION



Atty Dkt.: 1430-264  
 C# M#  
 Group Art Unit: 1633  
 Examiner: C.X. Qian  
 Date: April 16, 2002

**RECEIVED**  
 APR 17 2002

TECH CENTER 1600/2900

Sir:

**AMENDMENT UNDER 37 CFR § 1.111**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

**Fees are attached as calculated below:**

Total effective claims after amendment 24 minus highest number  
 previously paid for 24 (at least 20) = x \$ 18.00 \$ 0.00

Independent claims after amendment 3 minus highest number  
 previously paid for 3 (at least 3) = 0 x \$ 84.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months) \$ 0.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00)  
 Please enter the previously unentered , filed  
 Submission attached

**Subtotal** \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract  
 Applicant claims "small entity" status.  Statement filed herewith -\$ 0.00

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00


Other: \$ 0.00

**TOTAL FEE ENCLOSED** \$ 0.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
 Arlington, Virginia 22201-4714  
 Telephone: (703) 816-4000  
 Facsimile: (703) 816-4100  
 GRT:ap

NIXON & VANDERHYE P.C.  
 By Atty: Gary R. Tanigawa  
 Reg. No. 43,180

Signature: 

RECEIVED

APR 17 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

In re Patent Application of

CHARO et al.

Appln. No. 09/763,462

Filed: May 1, 2001

FOR: METHOD OF DNA VACCINATION



Atty. Ref.: 1430-264

Group Art Unit: 1633

Examiner: C.X. Qian

AMENDMENT UNDER 37 CFR § 1.111

April 16, 2002

Hon. Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the pending Office Action (Paper No. 8) mailed January 16, 2002, entry and consideration of the following amendments and remarks are respectfully requested.

IN THE CLAIMS

Kindly enter the following amended claims.

14. (Amended) A vaccine composition comprising a nucleotide sequence which encodes for an antigenic peptide associated with a disease state and which is within an appropriate vector, and a Schiff base forming compound which will enhance both humoral and cellular immune responses in a mammal which are initiated by the antigenic peptide, the compound being selected from the group consisting of:

4-(2-formyl-3-hydroxyphenoxy)methyl)benzoic acid;

5-(2-formyl-3-hydroxyphenoxy)pentanamide;

*N,N*-diethyl 5-(2-formyl-3-hydroxyphenoxy)pentanamide;

*N*-isopropyl 5-(2-formyl-3-hydroxyphenoxy)pentanamide;

ethyl 5-(2-formyl-3-hydroxyphenoxy)pentanoate;

5-(2-formyl-3-hydroxyphenoxy)pentanonitrile;